Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...

LIVER tumors, usually hepatomas, are relatively frequent in cases of hepatic cirrhosis, occurring in approximately 3 or 4 per cent of patients with alcoholic cirrhosis and in a somewhat higher ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

The investigators in a recent study found that prior thrombotic events and leukocytosis were linked to subsequent thrombotic events in general, and prior arterial events and hyperlipidemia were linked ...

Background A 16-year-old white male with a history of obstructive uropathy presented to a pediatric outpatient clinic with a first syncope. At presentation, he had a hemoglobin level of 220 g/l, a ...

Clinicians often encounter patients with hypogonadism in association with declining endogenous testosterone production that occurs as men age. This is sometimes referred to as andropause. Signs and ...

December 8, 2012 — Atlanta, GA — Maintaining a lower hematocrit (HCT) can help lower the risk for cardiovascular (CV) death in patients with polycythemia vera, according to the results of a new study.

The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...

Los Angeles, USA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Polycythemia Vera Pipeline Report presents an Updated Clinical Data of all the companies working in the Polycythemia Vera drug development scenario.

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...

The FDA has approved Jakafi (ruxolitinib) as a treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, based on findings from the phase 3 RESPONSE trial. The Food ...

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...